Preparation of vitexin albumin nanoparticles and its pharmacokinetic study.
10.19540/j.cnki.cjcmm.20230627.301
- Author:
Xue ZHANG
1
;
Qiang WANG
1
;
Jian-Quan PAN
1
;
Si-Wei WANG
1
;
Cheng-Yuan WU
1
;
Yun-Na CHEN
2
;
Feng-Ling WANG
3
;
Lei WANG
4
;
Wei-Dong CHEN
4
Author Information
1. School of Pharmacy, Anhui University of Chinese Medicine Hefei 230012, China.
2. MOE-Key Laboratory of Molecular Biology (Brain Diseases), Anhui University of Chinese Medicine Hefei 230012, China.
3. School of Pharmacy, Anhui University of Chinese Medicine Hefei 230012, China Hefei Hospital Affiliated to Anhui Medical University Hefei 230011, China School of Pharmacy, Anhui Medical University Hefei 230032, China.
4. School of Pharmacy, Anhui University of Chinese Medicine Hefei 230012, China MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials Hefei 230012, China Anhui Province Key Laboratory of Chinese Medicinal Formula Hefei 230012, China.
- Publication Type:Journal Article
- Keywords:
albumin nanoparticles;
micro powders;
plasma pharmacokinetics;
quality evaluation;
vitexin
- MeSH:
Rats;
Animals;
Serum Albumin, Bovine/chemistry*;
Chromatography, Liquid;
Tandem Mass Spectrometry;
Nanoparticles/chemistry*;
Particle Size;
Drug Carriers/chemistry*
- From:
China Journal of Chinese Materia Medica
2023;48(19):5205-5215
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to prepare vitexin albumin nanoparticles(VT-BSA-NPs) to alleviate the low bioavailability of vitexin(VT) in vivo due to its poor water solubility. VT micro powders were prepared by the antisolvent crystallization method, and the morphology, size, and physicochemical properties of VT micro powders were studied. The results showed that the VT micro powder had a particle size of(187.13±7.15) nm, an approximate spherical morphology, and a uniform size distribution. Compared with VT, the chemical structure of VT micro powders has not changed. VT-BSA-NPs were prepared from VT micro powders by desolvation-crosslinking curing method. The preparation process was screened by single factor test and orthogonal test, and the quality evaluation of the optimal prescription particle size, PDI, Zeta potential, EE, and morphology was performed. The results showed that the average particle size of VT-BSA-NPs was(124.33±0.47) nm; the PDI was 0.184±0.012; the Zeta potential was(-48.83±2.20) mV, and the encapsulation rate was 83.43%±0.39%, all of which met the formulation-related requirements. The morphological results showed that the VT-BSA-NPs were approximately spherical in appearance, regular in shape, and without adhesion on the surface. In vitro release results showed a significantly reduced release rate of VT-BSA-NPs compared with VT, indicating a good sustained release effect. LC-MS/MS was used to establish an analytical method for in vivo analysis of VT and study the plasma pharmacokinetics of VT-BSA-NPs in rats. The results showed that the specificity of the analytical method was good, and the extraction recovery was more than 90%. Compared with VT and VT micro powders, VT-BSA-NPs could significantly increase AUC, MRT, and t_(1/2), which was beneficial to improve the bioavailability of VT.
